Literature DB >> 21143050

The Melbourne Colorectal Cancer Study: reflections on a 30-year experience.

Gabriel A Kune1.   

Abstract

This article reflects on 30 years of conducting the Melbourne Colorectal Cancer Study, a comprehensive, population-based investigation of colorectal cancer (CRC). The study had an incidence arm, a case-control arm and a survival arm, and contributed considerable knowledge about CRC risk, aetiology, prevention and screening. The incidence arm: confirmed high rates of CRC in Australia and the prevalent view that rates rise in first-generation immigrants from countries with low rates of CRC; and enabled the first report of high rates of colon cancer among Australian Jewish people and the first report of high rectal cancer rates anywhere. The case-control arm elicited: the contribution of family history, antecedent colorectal polypectomy and multiple antecedent stressful life events to CRC risk; the risk of rectal cancer in habitual beer drinkers; the first dietary risk score (emphasising the importance of a diet pursued over adult life that is high in foods of plant origin and fish, and low in fat and red meat); and the highly protective effect of regular aspirin use (stimulating much research globally, with the possibility of aspirin becoming an important preventive agent). The survival arm: found an adjusted CRC-specific 5-year survival rate of 42% among patients with CRC and 85% among matched control subjects; confirmed cancer stage as the most important single determinant of survival; and found that the survival rate among people with the earliest stage of CRC was only marginally lower than that of matched community control subjects, underlining the importance of early detection.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21143050     DOI: 10.5694/j.1326-5377.2010.tb04093.x

Source DB:  PubMed          Journal:  Med J Aust        ISSN: 0025-729X            Impact factor:   7.738


  7 in total

1.  FXR silencing in human colon cancer by DNA methylation and KRAS signaling.

Authors:  Ann M Bailey; Le Zhan; Dipen Maru; Imad Shureiqi; Curtis R Pickering; Galina Kiriakova; Julie Izzo; Nan He; Caimiao Wei; Veerabhadran Baladandayuthapani; Han Liang; Scott Kopetz; Garth Powis; Grace L Guo
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2013-10-31       Impact factor: 4.052

Review 2.  Aspirin for the prevention of colorectal cancer.

Authors:  X Garcia-Albeniz; A T Chan
Journal:  Best Pract Res Clin Gastroenterol       Date:  2011-08       Impact factor: 3.043

Review 3.  Aspirin in the chemoprevention of colorectal neoplasia: an overview.

Authors:  Andrew T Chan; Nadir Arber; John Burn; Whay Kuang Chia; Peter Elwood; Mark A Hull; Richard F Logan; Peter M Rothwell; Karsten Schrör; John A Baron
Journal:  Cancer Prev Res (Phila)       Date:  2011-11-14

4.  Epidemiology and Survival of Colorectal Cancer in Lebanon: A Sub-National Retrospective Analysis.

Authors:  Rajaa Chatila; Joseph Mansour; Anas Mugharbil; Ghazi Nsouli; Lana O'Son; Edouard Sayad; Mary E Deeb
Journal:  Cancer Control       Date:  2021 Jan-Dec       Impact factor: 3.302

5.  Distinct Urinary Metabolic Biomarkers of Human Colorectal Cancer.

Authors:  Chang Zhu; Fengjie Huang; Yang Li; Chaowei Zhu; Kejun Zhou; Haihui Xie; Ligang Xia; Guoxiang Xie
Journal:  Dis Markers       Date:  2022-04-26       Impact factor: 3.464

Review 6.  Next-generation sequencing: insights to advance clinical investigations of the microbiome.

Authors:  Caroline R Wensel; Jennifer L Pluznick; Steven L Salzberg; Cynthia L Sears
Journal:  J Clin Invest       Date:  2022-04-01       Impact factor: 14.808

Review 7.  Microbial Metabolites in Colorectal Cancer: Basic and Clinical Implications.

Authors:  Yao Peng; Yuqiang Nie; Jun Yu; Chi Chun Wong
Journal:  Metabolites       Date:  2021-03-10
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.